Search the Newsreel

Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis

Oppenheimer initiated coverage on Palisade Bio (NASDAQ: PALI) with a Buy rating, highlighting its potential in the inflammatory bowel disease market. The company's lead drug, PALI-2108, a once-daily oral PDE4 inhibitor, is seen as a strong candidate for ulcerative colitis and Crohn's disease due …

Palisade Bio jumps following Oppenheimer outperform initiation (PALI:NASDAQ)

Oppenheimer initiated coverage of Palisade Bio (PALI) with an outperform rating and an $8 price target, representing a 321% upside. This initiation caused the stock to jump approximately 14% in morning trading. Analyst Leland Gershell views strong potential in the company's PALI-2108.

PALI Initiates Coverage On by Oppenheimer -- Rating 'Outperform'

Oppenheimer has initiated coverage on Palisade Bio (PALI) with an 'Outperform' rating and a price target of $8.00, suggesting significant upside from its current price of $1.90. Despite a low GF Score™ of 35/100 due to profitability challenges typical for a clinical-stage biotech, the …

GoodVision AI Japan expansion tied to Calisa Acquisition (ALIS) merger plans

Calisa Acquisition Corp (ALIS) announced that its proposed merger partner, GoodVision AI Inc., revealed the establishment of its first next-generation AI Factory in Japan on July 16, 2026. This communication is made in the context of their Business Combination Agreement, with cautionary notes emphasizing …

Calisa Acquisition (NASDAQ: ALIS) backs 100 MW GoodVision AI factory plan in Japan

Calisa Acquisition Corp. (NASDAQ: ALIS) announced support for its proposed business combination partner, GoodVision AI, in its plan to develop a 100 MW AI Factory network in Japan through a strategic cooperation with AI Storm Co., Ltd. The initiative will begin with a 2 …

PALI Forecast — Price Target — Prediction for 2027

We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn

Palisade Bio Inc reports results for the quarter ended June 30 - Earnings Summary

Palisade Bio Inc.’s Stock Climbs Amid Patent News: What’s Next?